Moderna, Inc NASDAQ:MRNA Shares Purchased by Lazard Asset Management LLC

The Zacks Biomedical and Genetics industry includes biopharmaceutical and biotechnology companies that develop high-profile drugs using path-breaking technology. These biologically processed drugs, which address virology, neuroscience, metabolism and rare diseases, are manufactured using live organisms. Moderna (MRNA) , a clinical-stage biotech company, is carrying out phase 3 trials of its Covid-19 vaccine, completing enrollment of 30,000 participants.

About Moderna Stock (NASDAQ:MRNA)

In a nutshell, it looks like the drugmaker’s vaccine technology can also be used to keep tumors from coming back after they’ve been surgically removed. We expect the Covid-19 shot to remain the primary driver of Moderna’s performance in 2022 as well. The global inoculation drive is still in the early stages, with the Bloomberg Vaccine Tracker estimating that vaccine doses have been administered to fully vaccinate just about 10% of the world’s population. This gives Moderna room to scale up further, with the company looking to boost production to as much as 3 billion doses in 2022. That said, 2022 is unlikely to be as profitable for the company, as more doses are likely sold to lower-income markets. For example, the World Health Organization’s Covid-19 Vaccines Global Access program could likely take on as much as 466 million doses from Moderna next year.

Zacks Mobile App

Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares in the last quarter. Allworth Financial LP raised its holdings in Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after acquiring an additional 101 shares during the period. TIAA Trust National Association boosted its holdings in shares of Moderna by 2.3% in the fourth quarter.

About MarketBeat

For example, Moderna’s shot currently costs as much as $37 per dose, and we think it is quite unlikely that the booster doses will command similar pricing. Moderna has a large development pipeline that includes another nine vaccines and 13 therapeutics in areas including immuno-oncology and rare diseases. Four of the company’s developments, including its CMV vaccine and personalized cancer vaccine, are in the phase 2 trials and any positive data surrounding these developments could also help the stock. [1] With Moderna poised to generate big profits from its Covid-19 shot (as much as $10 billion this year), it will have the resources to bolster its pipeline further in the coming years. Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases.

A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer. Since most companies in the biotech sector do not have approved drugs, valuing these companies becomes a complex process. If approved, mRNA-4157 won’t be the first cancer vaccine for melanoma patients.

1. We expect the Covid-19 shot to remain the primary driver of Moderna’s performance in 2022 as well.
2. Ms. Litchfield and her Merck team need to acquire Moderna’s50% interest in the Combination for what it supports in terms of market capprotection, whether in full upfront or with some CVR mechanism.
3. Food and Drug Administration (FDA) approved Imlygic from Amgen to treat melanoma patients who relapse after surgery.
4. The U.S. government has awarded $176 million to Moderna to advance development of its bird flu vaccine, the company said on Tuesday, as concerns rise over a multi-state outbreak of H5N1 virus in dairy…

Gilead Sciences earlier acquired CymaBay Therapeutics to strengthen its liver disease portfolio and Vertex Pharmaceuticals acquired Alpine Immune Sciences. Eli Lilly recently announced https://www.1investing.in/ that it will acquire Morphic Therapeutics for approximately $3.2 billion. This means that analysts believe this stock is likely to outperform the market over the next twelve months.

The company is also working to expand the drug’s label for the larger commercial opportunity in other disorders like Alzheimer’s disease agitation and smoking cessation. The acquisition of Sunosi diversified the company’s portfolio to two marketed drugs. An unfavorable outcome from a crucial trial on a promising candidate is a huge setback, particularly for smaller biotechs, which are mostly one-trick ponies. The leading biotechs face other headwinds, including declining sales of high-profile drugs due to intensifying competition. The influx of cash from big pharma/biotech companies further propels the biotech sector.

According to 16 analysts, the average rating for MRNA stock is “Buy.” The 12-month stock price forecast is $142.86, which is an increase of 20.35% from the latest price. Since Merck and Moderna share the Combination costs andprofits 50-50, Merck can only count on up to $70B market cap value from thatsource. The other up to $70B of market cap value resides with Moderna, itself with a market cap below $50B that covers not only half of the Combination but also the large infectious, latent, and rare disease vaccines and over $10B in cash.

WOBURN, Mass.–(BUSINESS WIRE)– #leveragen–Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has e… Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Furthermore, the company tangible net worth formula has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors.

The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature’s DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020. However, we don’t expect a major impact on the long-term potential for the RSV vaccines from GSK, Pfizer, and Moderna.

The company could supply about 40 million doses in the United States in 2020 if the data is positive and regulators approve the vaccine. This could make the Novavax vaccine – which can be produced at scale and easily distributed – popular if the pricing is suitably adjusted. See our indicative theme on Covid-19 Vaccine stocks for more details on the performance of key U.S. based companies working on Covid-19 vaccines. Jointly developed by Merck and Moderna, mRNA-4157 (V940) is a novel mRNA-based individualized neoantigen therapy that is combined with Merck’s blockbuster cancer drug Keytruda. Under the current collaboration, the two companies share the costs and any potential profits equally under the collaboration—a true 50/50 partnership. Cedar Wealth Management LLC increased its stake in shares of Moderna by 45.0% in the first quarter.

Moreover, the Covid-19 vaccine market is also likely to get increasingly competitive as time goes on, as new players enter the fray and existing players scale up capacity. Pfizer, for instance, says that it could scale up capacity from two billion doses this year to as much as three billion in 2022. Considering this, we think that investors will need to evaluate these companies based on the potential of their future pipelines, rather than just focusing on their Covid vaccines. Royal Bank of Canada lifted their target price on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a report on Monday, June 3rd.

It accounted for around 40% of Merck’s sales last year, a 19% bump from 2022, and already in the first quarter of 2024 earned 20% more compared to the same period last year. When the drug loses its patent exclusivity in 2028, it could see a 19% drop in sales in the first year as biosimilars come online, according to a report from Pharmaceutical Today. Axsome’s Auvelity (for major depressive disorder) has witnessed a steady uptake and the momentum is likely to continue in 2024.